Skin aging, wound healing, hair growth
Not FDA-approved
1973 by Loren Pickart
Topical, SC/IM (injectable)
Overview
GHK-Cu (Copper Tripeptide-1) is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK). The parent tripeptide GHK was isolated from human plasma and albumin in 1973 by Loren Pickart; it readily complexes with copper ions to form GHK-Cu [1]. Early mechanistic and tissue-repair literature on GHK-Cu appeared in the 1980s, with fibroblast collagen studies among the first experimental evidence of its biological activity [2].
Unlike purely synthetic research peptides, GHK-Cu is endogenous; it occurs naturally in human plasma, saliva, and urine, with plasma concentrations declining with age. This age-related decline has fueled research interest in its potential roles in skin repair and regeneration [1].
Research Areas and Claims
Human evidence for GHK-Cu is concentrated in dermatology and wound care. The following areas reflect both controlled trial findings and preclinical evidence:
-
Skin Aging & Photoaging: Topical GHK-Cu has been studied in randomized controlled trials for reduction of wrinkle volume/depth, improvements in skin laxity, and increased skin density and thickness [3][4].
-
Wound Healing: A 1994 randomized vehicle-controlled trial demonstrated that topical GHK-Cu ("lamin gel") increased the percentage of ulcer closure and accelerated closure rate in diabetic foot ulcers versus standard care [5].
-
Hair & Scalp: Claims for GHK-Cu promoting hair growth exist and are commonly cited in cosmetic contexts. However, robust controlled human clinical evidence for hair regrowth is limited compared to established hair-loss therapies [6].
-
Broad Tissue Repair / Gene Expression: Reviews describe wide transcriptional changes consistent with anti-inflammatory and tissue-repair patterns in preclinical and omics research. These are not the same as proven clinical outcomes [6].
Mechanism of Action
Note: GHK-Cu's mechanisms are partially understood. The following pathways are supported by cellular and experimental evidence, and are consistent with, but not always proven to produce, its observed clinical effects.
- Copper Binding & Delivery: GHK binds copper ions (Cu²⁺) strongly and may act as a local copper-delivery and availability modulator in tissues, influencing enzymes dependent on copper as a cofactor [1].
- Extracellular Matrix (ECM) Remodeling: Cellular studies demonstrate effects on collagen synthesis and ECM pathways in fibroblasts, with the earliest evidence dating to 1988 [2].
- Protease Regulation / Wound-Repair Signaling: GHK-Cu influences pathways involving matrix metalloproteinases (e.g., MMP-2) and wound-repair signaling networks in experimental systems, consistent with remodeling activity [7].
- Broad Gene Expression Effects: Reviews describe wide transcriptional changes affecting hundreds of genes with patterns consistent with tissue repair and anti-inflammatory signaling. These effects are primarily characterized in preclinical and omics contexts [6].
Clinical Trials
Human controlled evidence for GHK-Cu is concentrated in dermatology and wound care, not systemic or "longevity" endpoints. The table below includes the peer-reviewed and abstract-level evidence available as of February 2026.
| Study & Year | Design | Route / Indication | Outcome / Status | Ref |
|---|---|---|---|---|
| Mulder et al. (1994) | Randomized, vehicle-controlled | Topical gel / Diabetic foot ulcers | Increased ulcer closure rate and % closure vs. vehicle/standard care | [5] |
| Facial photoaging (~2002) | Placebo-controlled (meeting abstract) | Topical cream / Photoaged skin | Reported improvements in laxity, fine lines, skin density (~12 weeks); full manuscript not available | [4][9] |
| Miller et al. (2006) | Clinical study, post-procedure | Topical / CO₂ laser-resurfaced skin | No significant objective improvement in erythema/wrinkles; higher patient satisfaction in GHK-Cu group | [8] |
| Badenhorst et al. (2016) | Randomized, double-blind | Topical serum / Facial wrinkles | Reduced wrinkle volume/depth; favorable vs. peptide comparator over 8 weeks | [3] |
Administration Methods
- Topical (creams/serums): Best-documented human use for skin endpoints (twice-daily application over 8–12 weeks in cosmetic studies) [3][4].
- Topical (wound gel): Studied in diabetic foot ulcers ("lamin gel" formulation) [5].
- Injectable (SC/IM): Used in some longevity and peptide clinics for systemic administration. No controlled human trials establishing efficacy or safety for systemic "longevity" outcomes have been identified [1][6].
- Oral: Not a standard evidence-based route for GHK-Cu. Oral copper supplements are not equivalent to GHK-Cu [1].
Important Safety & Regulatory Information
- FDA Status: Not FDA-Approved. GHK-Cu is not approved by the FDA for any therapeutic indication. When sold as a cosmetic ingredient, it is regulated differently from drugs; when sold as a research peptide for injectable use, it falls into an unregulated research chemical category.
- Systemic Use: No Established Evidence Base: Injectable (SC/IM) GHK-Cu for longevity or anti-aging is used by some clinics, but no controlled human trials have established efficacy or safety for these systemic indications [6].
- Claims to Avoid: "Reverses aging," "regenerates organs," "proven longevity therapy," "clinically proven for hair regrowth," and "FDA-approved anti-aging" are not supported by the clinical evidence base. Effects vary; some trials show limited objective benefit [8].
- Copper Toxicity: Excessive copper intake carries known risks. The relationship between GHK-Cu administration and systemic copper levels warrants caution, particularly with injectable routes.
Market Overview
Please note: The following data is based on February 2026 pricing across surveyed vendors. All products are strictly sold as research chemicals or cosmetic ingredients. Prices fluctuate based on volume, batch, purity, and presentation. Vendors are rated A (Great) or B (Good) based on quality and transparency assessment.
Injectable
Lyophilized PowderReconstituted for SC/IM research use. Standard vial sizes: 50mg, 100mg.
- Price Range: $0.60 – $1.40 per mg
- Typical Sizes: 50mg, 100mg vials
- Vendors with pricing: 8 surveyed
Topical
Serums & PowdersAvailable as cosmetic powder, pre-formulated serum, or topical solution. Best-documented route.
- Price Range: $37.99–$200 per product
- Formats: 3% serum, topical serum, 200mg powder
- Vendors: 3 surveyed
Oral
CapsulesOral GHK-Cu capsules exist but this is not a standard evidence-based route. Oral copper ≠ GHK-Cu.
- Price: ~$1.375/mg
- Typical Sizes: 60 caps × 2mg (120mg total)
- Vendors: 1 identified
Vendor Directory
Data collected February 2026. Tables are split by formulation type. Vendors without public pricing are noted.
Injectable: Lyophilized Powder (SC/IM)
| Vendor | Sizes (mg) | Price Range ($/mg) | Website |
|---|---|---|---|
| Precision Peptide Co | 50 | $0.60 | precisionpeptideco.com |
| Peptidology | ~54 / ~114 (batch) | $0.65 – $0.86 | peptidology.co |
| Nuscience Peptides | 50 / 100 | $0.80 – $0.90 | nusciencepeptides.com |
| Biolongevity Labs | 50 | $1.19 | biolongevitylabs.com |
| Accelerate Labs | 50 | $1.40 | acceleratelabs.co |
| Pharma Grade Peptides | 50 | $1.40 | pharmagradepeptides.com |
| Bulk Peptide Supply | 100 (10×10mg) | $2.35 | bulkpeptidesupply.com |
| Peptide Sciences | 50 | $1.25 – $1.40 | peptidesciences.com |
Topical: Serums & Cosmetic Powders
| Vendor | Format | Price | Website |
|---|---|---|---|
| Precision Peptide Co | Topical serum | $37.99 | precisionpeptideco.com |
| Nuscience Peptides | 3% serum | $59.99 | nusciencepeptides.com |
| Peptide Sciences | 200mg cosmetic powder | $200 ($1.00/mg) | peptidesciences.com |
Oral: Capsules
| Vendor | Format | Size (mg) | Price ($/mg) | Website |
|---|---|---|---|---|
| Peptide Sciences | Capsules (2mg/cap × 60) | 120 total | $1.375 | peptidesciences.com |
* Data Notes: Data collected February 2026. All products sold strictly for research or cosmetic purposes. Prices subject to change. Vendors without public pricing excluded from pricing columns. Injectable $/mg figures are based on listed catalog prices and stated mg per vial.
References
- Pickart L. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." (2015). PMC4508379
- Maquart F-X, Pickart L, Laurent M, et al. "Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺." (1988). ScienceDirect
- Badenhorst T, Svirskis D, Venter P, et al. "Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production and facial wrinkle parameters." (2016). Walsh Medical Media
- Gorouhi F, Maibach H. "Role of topical peptides in preventing or treating aged skin." (2009). Wiley Online Library
- Mulder GD, Patt L, Sanders L, Rosenstock J. "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper." (1994). PubMed 17147644
- Pickart L, Margolina A. "Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data." (2018). PMC6073405
- Siméon A, Wegrowski Y, Bontemps Y, Maquart F-X. "The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu²⁺ and MMP regulation." (2000). PubMed 11045606
- Miller TR, Smith DJ Jr, et al. "Effects of topical copper tripeptide complex on CO₂ laser-resurfaced skin." (2006). PubMed 16847171
- Dermatology Times. "Copper-containing cosmetics improve complexion." (2002). dermatologytimes.com